JP2018512170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512170A5 JP2018512170A5 JP2018501142A JP2018501142A JP2018512170A5 JP 2018512170 A5 JP2018512170 A5 JP 2018512170A5 JP 2018501142 A JP2018501142 A JP 2018501142A JP 2018501142 A JP2018501142 A JP 2018501142A JP 2018512170 A5 JP2018512170 A5 JP 2018512170A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 193
- 238000000034 method Methods 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 20
- 241000124008 Mammalia Species 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 3
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 3
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 101150063370 Gzmb gene Proteins 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 3
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 3
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 3
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 229940022399 cancer vaccine Drugs 0.000 claims 3
- 238000009566 cancer vaccine Methods 0.000 claims 3
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 101100179076 Rattus norvegicus Icos gene Proteins 0.000 claims 2
- 102000043396 human ICOS Human genes 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 101100179075 Mus musculus Icos gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 229940030325 tumor cell vaccine Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148509A JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562137034P | 2015-03-23 | 2015-03-23 | |
| US62/137,034 | 2015-03-23 | ||
| US201562147484P | 2015-04-14 | 2015-04-14 | |
| US62/147,484 | 2015-04-14 | ||
| US201562156588P | 2015-05-04 | 2015-05-04 | |
| US62/156,588 | 2015-05-04 | ||
| US201562242489P | 2015-10-16 | 2015-10-16 | |
| US62/242,489 | 2015-10-16 | ||
| US201562255635P | 2015-11-16 | 2015-11-16 | |
| US62/255,635 | 2015-11-16 | ||
| PCT/US2016/023524 WO2016154177A2 (en) | 2015-03-23 | 2016-03-22 | Antibodies to icos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148509A Division JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512170A JP2018512170A (ja) | 2018-05-17 |
| JP2018512170A5 true JP2018512170A5 (cg-RX-API-DMAC7.html) | 2019-04-25 |
| JP6944924B2 JP6944924B2 (ja) | 2021-10-06 |
Family
ID=56978549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501142A Active JP6944924B2 (ja) | 2015-03-23 | 2016-03-22 | Ｉｃｏｓに対する抗体 |
| JP2021148509A Pending JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148509A Pending JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Country Status (34)
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5960597B2 (ja) * | 2009-09-30 | 2016-08-02 | メモリアル スローン−ケタリング キャンサー センター | 癌治療のための併用免疫療法 |
| CA3050674C (en) | 2011-03-31 | 2021-10-12 | Julien FAGET | Antibodies directed against icos and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN113456812B (zh) | 2015-01-09 | 2024-08-20 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
| DK3273992T3 (da) * | 2015-03-23 | 2020-07-27 | Jounce Therapeutics Inc | Antistoffer mod ICOS |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| KR20180066236A (ko) | 2015-10-22 | 2018-06-18 | 조운스 테라퓨틱스, 인크. | Icos 발현을 계측하기 위한 유전자 특질 |
| SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| BR112018070602A2 (pt) | 2016-04-07 | 2019-02-05 | Glaxosmithkline Ip Dev Ltd | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| CA3032897A1 (en) * | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018115859A1 (en) * | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| JP7290568B2 (ja) * | 2016-12-20 | 2023-06-13 | カイマブ・リミテッド | 癌免疫療法のための併用療法での多重特異性抗体 |
| CA3052767A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| US20200024351A1 (en) * | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| CA3066038A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| JP2020522555A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組み合わせ療法 |
| CA3066007A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| CA3065553A1 (en) * | 2017-06-18 | 2018-12-27 | Kindred Biosciences, Inc. | Il17a antibodies and antagonists for veterinary use |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019005762A1 (en) * | 2017-06-26 | 2019-01-03 | Abbvie Inc. | TREATMENT OF NON-SMALL CELL LUNG CANCER |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| IL272183B1 (en) * | 2017-08-11 | 2025-10-01 | Genentech Inc | Anti-CD8 antibodies and their uses |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| AU2018335876B2 (en) | 2017-09-22 | 2024-03-14 | University Of Washington | In situ combinatorial labeling of cellular molecules |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| US10723798B2 (en) | 2017-12-22 | 2020-07-28 | Jounce Therapeutics, Inc. | Antibodies to LILRB2 |
| TW202000891A (zh) | 2018-03-07 | 2020-01-01 | 英商葛蘭素史克智慧財產發展有限公司 | 純化抗體之方法 |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| CN112703012A (zh) * | 2018-05-14 | 2021-04-23 | 震动疗法公司 | 治疗癌症的方法 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| BR112020023451A2 (pt) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | terapia combinada |
| US20210260033A1 (en) | 2018-05-31 | 2021-08-26 | Glaxosmithkline Intellectual Property Development Limited | Combined therapy with icos binding proteins and argininemethyltransferase inhibitors |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| WO2020081905A1 (en) | 2018-10-18 | 2020-04-23 | Jounce Therapeutics, Inc | Methods for treating cancer |
| BR112021007082A2 (pt) | 2018-10-22 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | dosagem |
| EP3870610A1 (en) | 2018-10-24 | 2021-09-01 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| EP3870299A1 (en) | 2018-10-26 | 2021-09-01 | Jounce Therapeutics, Inc. | Methods of treating cancer |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| WO2020232375A1 (en) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| US11878009B2 (en) | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| US20220389106A1 (en) * | 2019-09-20 | 2022-12-08 | Board Of Regents, The University Of Texas System | Anti-epha10 antibodies and methods of use thereof |
| US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
| WO2021119753A1 (en) | 2019-12-18 | 2021-06-24 | Ctxt Pty Limited | Compounds |
| CN115244175A (zh) | 2020-01-07 | 2022-10-25 | 得克萨斯大学体系董事会 | 用于癌症治疗的改进的人甲硫腺苷/腺苷消耗酶变体 |
| EP4090771A1 (en) | 2020-01-13 | 2022-11-23 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| JP2023521228A (ja) | 2020-04-14 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の併用療法 |
| JP2023521465A (ja) | 2020-04-14 | 2023-05-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療 |
| AU2021257570A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CN115916821A (zh) | 2020-04-20 | 2023-04-04 | 震动疗法股份有限公司 | 用于疫苗接种和感染性疾病的治疗的组合物和方法 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022081841A1 (en) * | 2020-10-16 | 2022-04-21 | Fred Hutchinson Cancer Research Center | Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1 |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| FI4267105T3 (fi) | 2020-12-28 | 2025-06-17 | Bristol Myers Squibb Co | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3219336A1 (en) * | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| EP4525991A1 (en) | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4583999A1 (en) | 2022-09-09 | 2025-07-16 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| EP1017723B1 (de) | 1997-09-23 | 2007-01-10 | Bundesrepublik Deutschland letztvertreten durch Den Direktor des Robert-Koch-Instituts | Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| ATE397457T1 (de) | 1998-12-03 | 2008-06-15 | Univ California | Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| SI1149114T1 (sl) | 1999-02-03 | 2014-08-29 | Amgen Inc. | Polipeptidi, vkljuäśeni v imunskem odgovoru |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| AU7599500A (en) | 1999-09-21 | 2001-04-24 | Genetics Institute Inc. | Novel gl50 molecules and uses therefor |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| NZ522844A (en) | 2000-06-28 | 2005-02-25 | Brigham & Womens Hospital | PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA03004793A (es) | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| US20030124149A1 (en) | 2001-07-06 | 2003-07-03 | Shalaby Shalaby W. | Bioactive absorbable microparticles as therapeutic vaccines |
| HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| EP1441759A2 (de) | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Zelluläre impfstoffe mit adjuvanzien |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING ANTIBODY COMPOSITION |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| NZ547279A (en) | 2003-10-22 | 2008-04-30 | Keck Graduate Inst | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| JP2008501638A (ja) * | 2004-04-23 | 2008-01-24 | ドイツ連邦共和国 | ＩＣＯＳ陽性細胞のｉｎｖｉｖｏ枯渇によるＴ細胞介在病態の治療方法 |
| EP1768695A4 (en) | 2004-06-29 | 2008-07-30 | Univ Johns Hopkins | IMPROVEMENT OF MEDICINE-INDUCED TOXICITY |
| DE602006011574D1 (de) | 2005-01-27 | 2010-02-25 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
| JP2006265155A (ja) | 2005-03-23 | 2006-10-05 | Link Genomics Kk | 癌の免疫療法 |
| NZ601439A (en) | 2005-06-08 | 2012-11-30 | Brigham & Womens Hospital | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008090959A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | エフェクター活性が増強された遺伝子組換え抗体組成物 |
| RU2549701C2 (ru) * | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| CA2769822C (en) * | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| JP5960597B2 (ja) | 2009-09-30 | 2016-08-02 | メモリアル スローン−ケタリング キャンサー センター | 癌治療のための併用免疫療法 |
| AU2010328347B2 (en) | 2009-12-07 | 2015-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for enhancing anti-tumor antibody therapy |
| US9133436B2 (en) * | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
| US9410205B2 (en) | 2010-02-18 | 2016-08-09 | New York University | Methods for predicting survival in metastatic melanoma patients |
| EP3243385B1 (en) * | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CA3050674C (en) * | 2011-03-31 | 2021-10-12 | Julien FAGET | Antibodies directed against icos and uses thereof |
| NO2872646T3 (cg-RX-API-DMAC7.html) | 2012-07-12 | 2018-01-27 | ||
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| CN105324362B (zh) | 2013-03-15 | 2017-05-24 | 百时美施贵宝公司 | Ido抑制剂 |
| MY197809A (en) | 2013-03-15 | 2023-07-18 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| DK3273992T3 (da) * | 2015-03-23 | 2020-07-27 | Jounce Therapeutics Inc | Antistoffer mod ICOS |
| KR20180066236A (ko) * | 2015-10-22 | 2018-06-18 | 조운스 테라퓨틱스, 인크. | Icos 발현을 계측하기 위한 유전자 특질 |
| CN109310763B (zh) * | 2016-06-10 | 2022-10-21 | Io治疗公司 | 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂 |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
-
2016
- 2016-03-22 DK DK16769535.2T patent/DK3273992T3/da active
- 2016-03-22 ES ES16769535T patent/ES2811345T3/es active Active
- 2016-03-22 CA CA2978185A patent/CA2978185A1/en active Pending
- 2016-03-22 SG SG10202001019TA patent/SG10202001019TA/en unknown
- 2016-03-22 RU RU2017137020A patent/RU2742241C2/ru active
- 2016-03-22 CN CN202210469652.4A patent/CN114907481A/zh active Pending
- 2016-03-22 HU HUE16769535A patent/HUE049938T2/hu unknown
- 2016-03-22 HR HRP20201090TT patent/HRP20201090T1/hr unknown
- 2016-03-22 JP JP2018501142A patent/JP6944924B2/ja active Active
- 2016-03-22 RS RS20200941A patent/RS60614B1/sr unknown
- 2016-03-22 ME MEP-2020-166A patent/ME03819B/me unknown
- 2016-03-22 EP EP20167918.0A patent/EP3735986A1/en not_active Withdrawn
- 2016-03-22 EA EA201792078A patent/EA037621B1/ru unknown
- 2016-03-22 BR BR112017020054A patent/BR112017020054A2/pt not_active Application Discontinuation
- 2016-03-22 PH PH1/2021/552158A patent/PH12021552158A1/en unknown
- 2016-03-22 SI SI201630870T patent/SI3273992T1/sl unknown
- 2016-03-22 KR KR1020237040603A patent/KR20230164243A/ko not_active Ceased
- 2016-03-22 US US15/076,867 patent/US10023635B2/en active Active
- 2016-03-22 CN CN201680026223.2A patent/CN107530428B/zh not_active Expired - Fee Related
- 2016-03-22 LT LTEP16769535.2T patent/LT3273992T/lt unknown
- 2016-03-22 PT PT167695352T patent/PT3273992T/pt unknown
- 2016-03-22 MX MX2017012129A patent/MX386500B/es unknown
- 2016-03-22 AU AU2016235362A patent/AU2016235362B2/en not_active Ceased
- 2016-03-22 PH PH1/2017/501748A patent/PH12017501748B1/en unknown
- 2016-03-22 SM SM20200444T patent/SMT202000444T1/it unknown
- 2016-03-22 MA MA053297A patent/MA53297A/fr unknown
- 2016-03-22 PL PL16769535T patent/PL3273992T3/pl unknown
- 2016-03-22 KR KR1020177030281A patent/KR20170129902A/ko not_active Abandoned
- 2016-03-22 TW TW105108884A patent/TWI719970B/zh active
- 2016-03-22 EP EP16769535.2A patent/EP3273992B1/en active Active
- 2016-03-22 WO PCT/US2016/023524 patent/WO2016154177A2/en not_active Ceased
- 2016-03-22 MD MDE20180112T patent/MD3273992T2/ro not_active IP Right Cessation
- 2016-03-22 SG SG11201707769VA patent/SG11201707769VA/en unknown
-
2017
- 2017-08-31 ZA ZA201705920A patent/ZA201705920B/en unknown
- 2017-09-05 IL IL254338A patent/IL254338B/en unknown
- 2017-09-22 CL CL2017002401A patent/CL2017002401A1/es unknown
- 2017-09-25 MX MX2021011667A patent/MX2021011667A/es unknown
- 2017-10-18 CO CONC2017/0010618A patent/CO2017010618A2/es unknown
- 2017-10-23 EC ECIEPI201770399A patent/ECSP17070399A/es unknown
-
2018
- 2018-06-20 US US16/012,867 patent/US10570203B2/en active Active
-
2020
- 2020-08-12 CY CY20201100755T patent/CY1123409T1/el unknown
- 2020-09-16 US US17/022,856 patent/US20210171635A1/en not_active Abandoned
-
2021
- 2021-09-13 JP JP2021148509A patent/JP2022002520A/ja active Pending
- 2021-09-29 IL IL286807A patent/IL286807A/en unknown
-
2022
- 2022-03-01 AU AU2022201408A patent/AU2022201408A1/en not_active Abandoned